RBC Capital analyst Gregory Renza maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report) on May 8 and set a price target of $35.00. The company’s shares closed yesterday at $13.90.
According to TipRanks, Renza is a 5-star analyst with an average return of 18.7% and a 47.62% success rate. Renza covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Agios Pharma, and Alpine Immune Sciences.
In addition to RBC Capital, Viridian Therapeutics also received a Buy from H.C. Wainwright’s Douglas Tsao in a report issued on May 9. However, on the same day, B.Riley Financial downgraded Viridian Therapeutics (NASDAQ: VRDN) to a Hold.
The company has a one-year high of $28.35 and a one-year low of $10.93. Currently, Viridian Therapeutics has an average volume of 920.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Viridian Therapeutics (VRDN) Company Description:
Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.
Read More on VRDN:
- Viridian Therapeutics price target lowered to $31 from $36 at Oppenheimer
- Viridian Therapeutics downgraded to Neutral from Buy at Ladenburg
- Viridian Therapeutics price target lowered to $27 from $37 at H.C. Wainwright
- Viridian Therapeutics downgraded to Neutral from Buy at B. Riley
- Viridian Therapeutics reports Q1 EPS (79c), consensus ($1.10)
